• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>European journal of hospital pharmacy practice: E.J.H.P. practice >Cellular immunotherapy: a new treatment for viral infections after allogeneic stem cell transplantation
【24h】

Cellular immunotherapy: a new treatment for viral infections after allogeneic stem cell transplantation

机译：细胞免疫疗法：同种异体干细胞移植后病毒感染的新疗法

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Allogeneic stem cell transplantation (alloSCT) aims for the replacement of the haematopoietic system of the patient with a donor-derived haematopoietic system, and is increasingly used for treatment of a variety of haematological malignancies and inherited haematopoietic disorders. In the absence of adequate numbers of virus-specific T cells, alloSCT recipients can be exposed to a prolonged period of increased risk for viral infections. The disrupted control of common viruses, such as cytomegalovirus, Epstein-Barr virus (EBV), and human adenovirus, may result in unrestrained viral replication leading to serious morbidity and mortality. Since the reconstitution of virus-specific T cells has been demonstrated to provide sustained protection from viral disease, the adoptive transfer of donor-derived virus-specific T cells may be a safe and effective treatment for viral infections after alloSCT. Haematologists, pharmacists, researchers, and biotechnology companies have cooperated to develop strategies for the isolation of virus-specific T cells from donor peripheral blood for adoptive transfer, to circumvent the infusion of donor T cells that may recognise healthy patient tissue and cause potentially lethal graft-versus-host disease (GvHD). Small non-randomised clinical trials have indicated that cellular immunotherapy for viral infections after alloSCT may be safe and effective. Technological and immunological advances have recently been translated towards clinically applicable methods for isolation and culture of virus-specific T cells, and are ready to be implemented in clinical studies. Using these methods, which should fully comply with current regulations for cellular therapy, the clinical benefit of cellular immunotherapy for viral infections after alloSCT can be further established.
机译：同种异体干细胞移植（alloSCT）的目标是用供体来源的造血系统替代患者的造血系统，并越来越多地用于治疗各种血液系统恶性肿瘤和遗传性造血疾病。在没有足够数量的病毒特异性T细胞的情况下，alloSCT受体可能会长时间暴露于病毒感染风险中。对常见病毒（如巨细胞病毒，爱泼斯坦-巴尔病毒（EBV）和人腺病毒）的控制受到破坏，可能导致不受限制的病毒复制，从而导致严重的发病率和死亡率。由于已经证明重组病毒特异性T细胞可以提供对病毒疾病的持续保护，因此，将供体来源的病毒特异性T细胞过继转移可能是alloSCT后病毒感染的安全有效方法。血液学家，药剂师，研究人员和生物技术公司已合作开发策略，从供体外周血中分离病毒特异性T细胞以进行过继转移，从而避免输注可能识别健康患者组织并可能致死性移植的供体T细胞。 -宿主疾病（GvHD）。小型的非随机临床试验表明，针对alloSCT后病毒感染的细胞免疫疗法可能是安全有效的。最近，技术和免疫学方面的进展已转化为用于分离和培养病毒特异性T细胞的临床适用方法，并准备在临床研究中实施。使用这些方法，这些方法应完全符合当前细胞疗法的法规，可以进一步确定针对alloSCT之后病毒感染的细胞免疫疗法的临床益处。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号